Loading…

WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment

Saved in:

Bibliographic Details
Published in:	Journal of hepatology 2024-06, Vol.80, p.S809-S810
Main Authors:	Yuen, Man-Fung, Heo, Jeong, Nahass, Ronald G., Wong, Grace Lai-Hung, Burda, Tatiana, Bhamidimarri, Kalyan Ram, Hu, Tsung-Hui, Nguyen, Tuan T., Lim, Young-Suk, Chen, Chi-Yi, Gordon, Stuart C., Holmes, Jacinta, Chuang, Wan-Long, Kohli, Anita, Alkhouri, Naim, Gray, Kevin, Thi, Emily P., Medvedeva, Elina, Eley, Timothy, Ganchua, Sharie C., Iott, Christina, Eill, Elizabeth, Espiritu, Christine L., Anderson, Mark, Fortney, Tiffany, Cloherty, Gavin, Sims, Karen D.
Format:	Article
Language:	English
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!